ūüéČ Health Canada Provides a No Objection Letter for ATMA‚Äôs N500 Phase II Clinical Trial Application

ATMA Advanced Psychedelic-assisted Therapy (PaT) Certification Program

Through a world-class didactic curriculum, in-person coaching, and participation in a Health Canada-approved clinical trial, students will be able to embody the roles of both the psychedelic guide and the participant, allowing for the students to gain an understanding of the medicine from multiple perspectives.‚Äč

Registration opens October 13, 2022

We offer a practicable and affordable approach to education and training to become psychedelic therapy providers, via our professional development course aimed at already competent mental healthcare practitioners. ATMA Advanced Psychedelic-assisted Therapy (PaT) Certification Program begins January 6, 2023.


Why take ATMA PaT training now

In 2018, the U.S. Food and Drug Administration declared psilocybin a ‚Äúbreakthrough therapy‚ÄĚ in treatment for severe depression.‚Ä謆

In 2019, Imperial College London launched the Centre for Psychedelic Research, while U.S. institutions including Yale, UC Berkeley, and Mount Sinai Hospital have established psychedelic research divisions that conduct clinical trials. To date, close to a hundred North American academic institutions have followed suit.‚Ä謆

‚ÄčOn the regulations front, in November 2020, Oregon voted to become the first U.S. state to legalize supervised psilocybin services in controlled and professionally facilitated settings. Licensing for psilocybin services will begin in January 2023, paving the way for mental healthcare professionals to offer psilocybin-assisted therapy. Colorado is expected to vote on similar measures in November 2022. There are legislative and regulatory proposals in 15 other states that seek to allow for psychedelic-assisted therapy to be practiced in some measure.‚Ä謆

‚ÄčThe demand for quality training programs will quickly outstrip the supply, as psychedelic therapy is rapidly reaching mainstream conversations and patients are increasingly asking their therapy providers about it. With Oregon‚Äôs legalization just months away, and Colorado on the heels of Oregon, thousands of mental healthcare professionals in and around those states will be seeking training in a relatively short period of time. Unfortunately, the infrastructure to train and support therapy providers is not where it should be. By taking your training now and staying current with the conversations, you will be ready to provide psychedelic-assisted therapy in a timely manner.‚Ä謆

Additionally, if you have patients who are suffering immensely and require immediate access to psilocybin-assisted therapy, you may be in a position to provide it as early as mid-2023 by using Oregon’s psilocybin facilitation services, and with sufficient training. ATMA offers support every step of the way as you work towards offering psychedelic-assisted therapy. 


Clinical Trials

ATMA is the only education and training provider who has successfully conducted a clinical trial and who has also repeatedly been approved by Health Canada to carry out further clinical trial phases.

The opportunity for our students to cross participate in our psilocybin clinical trials (should¬†they meet clinical trial requirements) and to gain experience in psychedelic medicines under¬†the scientific standards of a clinical setting cannot be understated.‚Äč

The clinical trial data, in addition to the sharing of experiences between hundreds of mental health professionals within our community, may very well be the most valuable and priceless parts of our program.  Clinical insights coming from the perspective of professionals regarding the utility of psychedelic therapy is crucial for therapists to have as a reference in order to provide effective psychedelic therapy themselves.


Supporting you take the steps towards offering safe and effective psychedelic-assisted therapy

Our approach to education and training involves expanding the number of mental healthcare providers who are able to provide PaT as quickly as possible. We offer a path and price-point that will encourage already competent therapy providers to participate in this treatment, which will help scale the number of psychedelic practitioners to meet the fast-growing demand.‚Äč‚Ä謆

Our approach focuses on professional development for mental healthcare professionals who are already equipped with the skillsets to provide therapy, and who also have heavy workloads. We offer training that is practicably relevant, and while we provide the sufficient amount of academic and philosophical knowledge that is required to safely and ethically practice in this field, we believe that no amount of knowledge can replace the experience that is gained from hands-on training. Although we do encourage further studies into the academic and philosophical realms of psychedelics, we do not believe that these are core competencies in providing PaT.  

This course is open to everyone who is interested in PaT. We believe that the psychedelic therapist and the psychedelic facilitator will have different parts to play in psychedelic-assisted therapy, and each role can benefit from the different aspects of this course. This course is not intended to train mental healthcare professionals to be facilitators, nor facilitators to be therapy providers, although the choice would be yours based on your preference and the regulatory options available.‚Ä謆

Ongoing support

We believe that on-the-job learning is equally as important as front-end education and training in the competency development of psychedelic therapists. 

Our commitment in guiding you in the adoption of PaT does not stop after our education and training courses end.‚Äč‚Äč We design and streamline systems, networks, and infrastructure to support mental healthcare professionals and therapy providers through the entire process of adopting psychedelic-assisted therapy into practice. ‚Ä謆

With our Community Business Platform, therapy providers will feel supported, and will have all the resources required to adopt and provide psychedelic-assisted therapy. 


Here's what's included in our program


View the lesson plan

The Advanced Psychedelic-Assisted Therapy (PaT) Training Course curriculum is building on the basic information and principles taught in the ATMA Introduction to PaT and is one of three components of the ATMA Advanced PaT Certification Program. The Advanced PaT Training Course will prepare you both for being a facilitator for those requesting a psychedelic therapeutic session, as well as for the preparation and/or integration of clients who may come to you for help with a psychedelic experience outside of your care.

Unit 1 - Fundamentals of Psychedelics

Topics include Definitions of Psychedelics, Overview of the different Psychedelic compounds, Traditions and History, Contemporary History and Research, Pharmacology, Drug Interactions and Adverse Events, and Microdosing Research

Topics include Indigenous Perspectives, Access for Diverse and Under-privileged Populations, Cultural Implications, Current Regulatory Status of Psychedelics.

Topics explore Psychedelic Expanded States of Consciousness as well as Non-Psychedelic Expanded States of Consciousness, Comparison/Contrast of Psilocybin and MDMA Experiences and Outcomes.

Unit 2 - Fundamentals of Psychedelic-Assisted Therapy

Topics include Core Competencies, Presence/Empathy/Humility/Non-Directive Support, Principles of Facilitation, Self-Care for the Facilitator.

Topics include Ethics Guidelines and Considerations, Diverse Group Considerations, Consent/Boundaries and Appropriate Touch, Consent/Boundary Considerations for Psilocybin and MDMA PaT, Harm Reduction in Challenging Situations and Adverse Events.

Topics include the Overview of ‚ÄúSet‚ÄĚ, Screening for Safe and Optimal Experiences, Preparing the Client for PaT, Effective Modalities for Preparing the Client.

Topics explore the importance of the Physical, Social and Cultural Environment, Elements of the Treatment Spaces, the Role of Music, and Individual vs Group Experiences.

Topics cover the Importance of Integration, Integration Models, Individual and Group Integration Considerations.

Topic explore Choosing the correct Psychedelic for the Client, Addressing issues including Addictions, PTSD, Palliative Care, Depression and Anxiety, Relationship Counselling, and Leadership/Personal Awareness/Enhancement.

Topics will explore Complementary Modalities to PaT with Specialists 


Affordable prices and payment plan options

Our Advanced Psychedelic-assisted Therapy (PaT) Certification Program begins January 6, 2023.

One-time payment 

$4197 USD

The ATMA Advanced Psychedelic-Assisted Therapy Certification (PaT)  Program consists of 3 components

***Equivalent US training programs NOT including experiential¬†component range between $8,000 – $12,000 USD‚Äč

ATMA Advanced PaT Training Course

Online lessons, assignments, quizzes (60 hours)

ATMA Advanced Intensive Coaching Training

In-person (30 hours)

ATMA Advanced Experiential Training

In-person (30 hours)



Upon completion of all 3 components, graduates will be offered the ATMA Psychedelic-Assisted Therapy Certification. Those who choose to complete only the First Component (the online didactic portion) will be issued a completion certificate for that component.

4 monthly payments

$1099 USD / month

4x monthly payments





Hear what our students have to say

This beautifully facilitated experience allowed me to witness firsthand the power of this medicine to bring us back into connection with ourselves, with each other, and with the world around us. I am most grateful for this opportunity and trust that this experience will serve as the path forward towards wider access for healthcare professionals. 

ATMA Clinical Trial Participant/Therapist

August 2022

Being able to experience psilocybin provides a profound impact in being able to support clients through their own experiences.  To be able to provide the general public this type of experience, I believe, will revolutionize the mental health crisis we are currently in.

ATMA Clinical Trial Participant/Therapist

August 2022

My personal experience through this trial showed me the incredible potential healing and life-changing capabilities of this medicine alongside the importance of those administering these medicines to have hand this experience for themselves..  Psilocybin brings us to a place that is ineffable but offers true healing potential.

ATMA Clinical Trial Participant/Therapist

August 2022


Questions about our Advanced PaT Certification Program?

We encourage our students to ask questions directly and you can arrange a quick call with us anytime.

Yes, all our offerings are open to Canadians and Americans, training, clinical trial and business services.

Health Canada is slowly opening the door for patient access to psilocybin and MDMA for therapy purposes. This program will provide qualified therapy providers with an understanding of these medicines, and will equip them with the leading-edge therapy protocols necessary to practice legal psychedelic-assisted therapy in the near future. 

Therapy providers interested in how this program can allow them to participate in the upcoming Oregon legal framework for Psilocybin Services in 2023, please see‚ÄĮOregon Services.¬†

At various clinics across Canada, currently being planned for Vancouver, Calgary, Toronto and Montreal.

While students are encouraged to participate in the clinical trial (an important element of working with psychedelics is to have first-hand experience with the medicine), we understand that some students may have contraindications to psilocybin, or do not meet the other inclusion/exclusion criteria of the trial, and are thus unable to partake in the experiential session. 

Nonetheless, students will still be able to embody the role of the psychedelic guide and learn how to effectively guide others through their psychedelic journeys. 

Yes, please contact us for more information on your eligibility. 


Sign up to get notified when registration opens!

Registration opens October 13, 2022.

Scroll to Top